Latest News and Press Releases

ADVANZ PHARMA’s response to the reversal of the suspension of the European Commission decision on the OCALIVA® conditional marketing authorisation in Europe The conditional marketing authorisation...

ADVANZ PHARMA’s response to European Commission revocation of conditional marketing authorisation for OCALIVA® in rare disease Primary Biliary Cholangitis (PBC) OCALIVA® is the only farnesoid X...

Dublin, March 12, 2024 (GLOBE NEWSWIRE) -- The "UDCA Market Size, Forecast, and Drug Insight - 2032" report has been added to ResearchAndMarkets.com's offering. This report encapsulates crucial...

Dublin, March 11, 2024 (GLOBE NEWSWIRE) -- The "Global Primary Biliary Cholangitis Therapeutics Market" report has been added to ResearchAndMarkets.com's offering. The global primary biliary...

Dublin, March 01, 2024 (GLOBE NEWSWIRE) -- The "OCALIVA Market Size, Forecast, and Drug Insight - 2032" report has been added to ResearchAndMarkets.com's offering.This research report provides...

Dublin, Nov. 10, 2023 (GLOBE NEWSWIRE) -- The "Global Non-Alcoholic Steatohepatitis Market (by Drug Type, Application Type, Distribution Type, & Region): Insights and Forecast with Potential...

Dublin, Oct. 04, 2023 (GLOBE NEWSWIRE) -- The "Primary Biliary Cholangitis Therapeutics Market By Drug type, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2023-2032"...

MONSEY, N.Y., Sept. 26, 2023 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT)...

Dublin, Sept. 08, 2023 (GLOBE NEWSWIRE) -- The "Non-Alcoholic Steatohepatitis Market by Drug Type, Disease Cause, Sales Channel, End User, and Region 2023-2028" report has been added to ...

Dublin, Aug. 22, 2023 (GLOBE NEWSWIRE) -- The "NASH Treatment & Therapeutics Market Report 2023-2033" report has been added to ResearchAndMarkets.com's offering. The report presents a...